Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Common Equity (2016 - 2025)

Argan's Common Equity history spans 15 years, with the latest figure at $419.7 million for Q4 2025.

  • For Q4 2025, Common Equity rose 27.69% year-over-year to $419.7 million; the TTM value through Oct 2025 reached $419.7 million, up 27.69%, while the annual FY2025 figure was $351.9 million, 20.94% up from the prior year.
  • Common Equity for Q4 2025 was $419.7 million at Argan, up from $393.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $419.7 million in Q4 2025 and bottomed at $271.7 million in Q4 2022.
  • The 5-year median for Common Equity is $315.2 million (2021), against an average of $319.9 million.
  • The largest annual shift saw Common Equity decreased 22.31% in 2022 before it rose 27.69% in 2025.
  • A 5-year view of Common Equity shows it stood at $349.8 million in 2021, then fell by 22.31% to $271.7 million in 2022, then grew by 4.82% to $284.8 million in 2023, then rose by 15.4% to $328.7 million in 2024, then increased by 27.69% to $419.7 million in 2025.
  • Per Business Quant, the three most recent readings for AGX's Common Equity are $419.7 million (Q4 2025), $393.2 million (Q3 2025), and $363.9 million (Q2 2025).